X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HK036 (tanfanercept) is a potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor (TNF). It is being evaluated for the treatment of dry eye disease.
Lead Product(s): Tanfanercept
Therapeutic Area: Ophthalmology Product Name: HL036
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2024
Details:
HL192 (ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, a master regulator associated with the development and maintenance of dopaminergic neurons, for the potential treatment of Parkinson's Disease.
Lead Product(s): HL192
Therapeutic Area: Neurology Product Name: HL192
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Daewoong Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
The collaboration aims to develop small-molecule, first-in-class disease-modifying therapies by targeting the modulation of mitochondrial quality control mechanisms such as mitophagy for Parkinson's patients by leveraging Vincere's proprietary AI platform.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Vincere Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 12, 2023
Details:
HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative disorders.
Lead Product(s): ATH-399A
Therapeutic Area: Neurology Product Name: ATH-399A
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: NurrOn Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 25, 2023
Details:
HL036 (tanfanercept) is a novel, potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor alpha for the treatment of dry eye disease, co-developed with Daewoong Pharmaceutical.
Lead Product(s): Tanfanercept
Therapeutic Area: Ophthalmology Product Name: HL036
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Daewoong Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2023
Details:
IMVT-1401 (batoclimab) is a fully human, subcutaneously administered antibody originated from HanAll, which selectively binds to and inhibits the neonatal Fc receptor (FcRn). It has demonstrated high potential as a new treatment option for gMG patients.
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: IMVT-1401
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nona Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402). In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level.
Lead Product(s): HL161ANS
Therapeutic Area: Immunology Product Name: IMVT-1402
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
